Etesevimab

Synonyms

Etesevimab, Anti-COVID-19 Monoclonal Antibody JS016, Anti-COVID-19 Spike Protein Monoclonal Antibody JS016, Anti-SARS-CoV-2 Monoclonal Antibody JS016, ETESEVIMAB, JS 016, JS-016, JS016

Thesaurus

An Fc-modified neutralizing, recombinant, human monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration of etesevimab, this agent specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. Immunologic Factor, Pharmacologic Substance

• NCI Thesaurus (external)

C173741.

This concise article on Etesevimab incorporates public domain text from the US National Library of Medicine.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.